1 / 32

MENINGOCOCCAL MENINGITIS (MCM) AT NEW DELHI & INDIA

MENINGOCOCCAL MENINGITIS (MCM) AT NEW DELHI & INDIA. Dr. A. K. AVASARALA MBBS, M.D. PROFESSOR & HEAD DEPT OF COMMUNITY MEDICINE & EPIDEMIOLOGY PRATHIMA INSTITUTE OF MEDICAL SCIENCES, KARIMNAGAR, A.P. INDIA: +91505417 avasarala@yahoo.com. PART-II

jschoen
Download Presentation

MENINGOCOCCAL MENINGITIS (MCM) AT NEW DELHI & INDIA

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript


  1. MENINGOCOCCAL MENINGITIS (MCM) AT NEW DELHI & INDIA Dr. A. K. AVASARALA MBBS, M.D. PROFESSOR & HEAD DEPT OF COMMUNITY MEDICINE & EPIDEMIOLOGY PRATHIMA INSTITUTE OF MEDICAL SCIENCES, KARIMNAGAR, A.P. INDIA: +91505417 avasarala@yahoo.com

  2. PART-II CLINICAL DISEASE, EPIDEMIOLOGY AND CONTROL

  3. DEFINITION • IT IS A PYOGENIC INFECTION OF MEMBRANES COVERING THE BRAIN AND SPINAL CORD ( DURA, PIA AND ARACNOID MEMBRANES) BY MENIINGO-COCCI • ALSO CALLED CEREBROSPINAL FEVER

  4. CLINICAL PRESENTATIONS • RESTRICTED TO NASOPHARYNX AS ASYMPTOMATIC CASES OR ONLY WITH LOCAL SYMPTOMS • INVASIVE WITH ACUTELY ILL SEPTICEMIC AND TOXIC • MENINGEAL

  5. CLINICAL PICTURE IN THE NEWBORN • MINIMAL AND VARIABLE, HENCE DIAGNOSIS DIFFICULT • SLUGGISH, LETHARGIC WITH UNUSUAL GAZE • DOES NOT TAKE FEED WELL , MAY VOMIT • HIGH PITCHED CRY AND CONVULSIONS • HYPOTHERMIA SEEN USUALLY, FEVER MAY BE THERE • TENSE AND BULGING ANTERIOR FONTANELLAE VERY USUAL

  6. CLINICAL PICTURE IN PRESCHOOL & SCHOOL CHILD • WIDE SPECTRUM OF SIGNS & SYMPTOMS IN THIS AGE GROUP AND MORE OBVIOUS • MODERATE TO HIGH FEVER • HEADACHE, VOMITING, PHOTOPHOBIA, CONVULSIONS, • NECK STIFFNESS, • NEUROLOGICAL IRRITATION • SKIN RASHES

  7. CLINICAL PICTURE IN < 2 YEAR OLD CLASSICAL SIGNS MAY NOT BE PRESENT BUT HIGH DEGREE OF SUSPICION WHEN THE FOLLOWING PICTURE IS SEEN • FEVER COMMON • MACULOPAPULAR PETECHIAL RASH IN HALF OF THE CASES • REFUSAL OF FEEDS • VOMITINGS, • ALTERED SENSORIUM • IRRITABILITY • BULGING FONTANELLAE • NEUROLOGICAL DEFICIT (EITHER MONOPLEGIA, HEMIPLEGIA AND SQUINT

  8. CLINICAL PICTURE IN THE ADULT • CLEARCUT PICTURE • FEVER, INTENSE HEADACHE • VOMITING, PHOTOPHOBIA, • NECKPAIN AND STIFFNESS • SIGNS OF MENINGEAL IRRITATION AND ALTERED SENSORIUM • SKIN RASHES • SIGNS AND SYMPTOMS OF SHOCK

  9. DIFFERENTIAL DIAGNOSIS IN NEONATE: SEPTICEMIA, GASTROENTERITIS, BIRTH HYPOXIA, BIRTH TRAUMA, RESPIRATORY INFECTIONS, HYPOGLYCEMIA, METABOLIC DISORDERS CAUSING CONVULSIONS AND KERNICTERUS IN OLDER CHILDREN AND ADULTS: ENCEPHALITIS, BRAIN ABSCESS, CEREBRAL MALARIA, ASEPTIC MENINGITIS, CARDIOVASCULAR ACCIDENTS, CRYPTOCOCCAL MENINGIT IS AND TUBERCULAR MENINGITIS

  10. DIAGNOSIS • MENINGOCOCCI ARE DEMONSTRATED BY LUMBAR PUNCTURE AND EXAMINATION OF CEREBRO SPINAL FLUID (CSF) & CULTURE OF CSF • BLOOD CULTURE • CULTURE FROM NASOPHARYNX • EXAMINATION OF PETECHIAL SKIN LESIONS • IMMUNOLOGICAL METHODS FOR ANTIBODIES (IFP, ELISA, CIEP)

  11. TREATMENT • ISOLATION OR SEPARATION • ALL PATIENTS NEED HOSPITALIZATION • SPECIFIC TREATMENT - FLUIDS - CEFTRIAXONE/CEFOTOXIME - AMPICILLIN ( NOT TO BE GIVEN IF HYPERSENSITIVE TO PENICILLIN) - CHLORAMPHENICOL • SUPPORTIVE THERAPY: FOR SHOCK AND CONVULSIONS

  12. EPIDEMIOLOGICAL INTERACTION • AGENT FACTORS TIME DISRIBUTION MCM HOST FACTORS ENVIRONMENT FACTORS PERSON DISTRIBUTION PLACE DISTRIBUTION

  13. THE CAUSATIVE AGENT • NEISSERIA MENINGITIDIS (MENINGO COCCUS) • BISCUIT SHAPED GRAM + VE DIPLOCOCCUS • SIZE & SHAPE VARIATION IN OLDER CULTURES DUE TO AUTOLYSIS • TRANSPARENT ,NON PIGMENTED, NONHEMOLYTIC COLONIES 1-5 MM SIZE

  14. MENINGO COCCI

  15. SERO GROUP TYPING • DEPEND UPON THE POLYSACCHARIDE CAPSULE • NINE SEROLOGICAL GROUPS IDENTIFIED • A, B, C, D, X , Y, Z , W-135, 29E • ALL THE SEROGROUPS ARE PATHOGENIC BUT A, B, C, Y ARE MOST NEUROVIRULENT • A AND C ARE MOST EPIDEMOGENIC

  16. MODE OF TRANSMISSION • HUMAN CASES AND THE CARRIERS ARE THE ONLY RESERVOIRS • TRANSMITTED BY DIRECT CONTACT (DROPLETS,DISCARGE FROM THE NOSE &THROAT OF THE PERSONS) • INCUBATION PERIOD = 3-4 DAYS • PERIOD OF COMMUNICABILITY IS AS LONG AS THE MENINGOCOOCI ARE PRESENT IN DISCARGES FROM NOSE, THROAT AND NASOPHARYNX

  17. PERSON FACTORS • POOR NUTRITIONAL STATUS & IMMUNITY • DRY NASAL MUCOSA • PHYSICAL EXERTION • FATIGUE • CARRIER STATE

  18. AGE PREDILICTION PRIMARILY A CHILD DISEASE BUT CAN AFFECT YOUNG ADULTS ALSO

  19. SEX PREDILICTION • MORE MALES ARE AFFECTED THAN FEMALES

  20. PLACE DISTRIBUTION • MCM IS ENDEMIC IN LARGE TOWNS • MORE COMMONLY IN PEOPLE LIVING IN CROWDED CONDITIONS

  21. TIME DISTRIBUTION • GREATEST INCIDENCE IN WINTER AND SPRING

  22. CARRIER STATE • TRANSMISSION OCCURS MORE OFTEN FROM CARRIERS RATHER THAN CASES • BY AND LARGE HIGH CARRIER RATE IS USUALLY ASSOCIATED WITH OUTBREAKS

  23. CONTROL MEASURES

  24. VACCINATION • COMPOSITION: 50 MICRO GRAMS OF “A” POLYSACHARIDE, 50 MICRO GRAMS OF “C” POLY SACHARIDE, 1 MG OF LACTOSE. • DOSE - 0.5 ML OF IRRESPECTIVE OF AGE GIVEN SUBCUTANEOUSLY. • EFFICACY– SEROGROUP “A’ CLINICAL EFFICACY = 85-95% SERO GROUP “A’ INDUCES ANTIBODY RESPONSE IN CHILDREN AS YOUNG AS 3 MONTHS OLD. • BUT SEROGROUP “C” DOES NOT INDUCE ANTIBODIES BEFORE 2 YEARS OF AGE. • SEROGROUP “Y” AND W-135 ARE SAFE AND IMMUNOGENIC IN ADULTS AND CHILDREN ABOVE AGE OF 2 YEARS.

  25. VACCINATION LIMITATIONS • LIMITED SHELF LIFE AFTER REVACCINATION • NO VACCINE IS AVAILABLE AGAINST GROUP B • SHORT INCUBATION PERIOD vis-à-vis MORE TIME TAKEN FOR THE DEVELOPMENT OF IMMUNITY • 4.UNSATISFACTORY RESPONSE VACCINATION UNDER 2 YEARS OF AGE WHICH IS THE HIGHEST SUSCEPTIBLE AGE-GROUP

  26. PRESENT STRATEGY FOR VACCINATION • ONLY HIGH RISK PEOPLE (HEATH CARE WORKERS, TRAVELLERS, PEOPLE LIVING IN OVERCROWDED PLACES) AND CLOSE CONTACTS HAVE TO BE VACCINATED.

  27. VACCINATION FOR CONTACTS • FORTUNATELY, WE HAVE QUADRIVALENT VACCINES AT PRESENT • PROTECTION OCCURS ONLY AFTER 14 DAYS OF VACCINATION • HENCE CHEMOPROPHYLAXIS IS PROVIDED WITH ANTIBIOTICS IN THE MEANTIME

  28. VACCINATION FOLLOWED BY +CHEMOPROPHYLAXIS FOR CLOSE CONTACTS • HOUSEHOLD MEMBERS • DAY-CARE CENTRE CONTACTS • ANYONE DIRECTLY EXPOSED TO THE PATIENT'S ORAL SECRETIONS OR RESPIRATORY DROPLETS.

  29. CHEMOPROPHYLAXISFOR CLOSE CONTACTS CIPROFLOXACIN, RIFAMPICIN, MINOCYCLINE, SPIRAMYCN, CEFTRIAXIONE • WITHIN 24 HOURSFOR • HOUSEHOLD • CONTACTS • CLOSE CONTACTS • HIGH RISK PERSONS WITH

  30. RISK COMMUNICATION THROUGH PUBLIC EDUCATION REGARDING • RISK FACTORS AND POSSIBLE CONTROL STRATEGIES • NOTIFICATION OF CASES AT THE EARLIEST • SURVEILLANCE FOR ACTIVE AND SUSTAINED COMMUNITY PARTICIPATION TO CONTROL THE EPIDEMIC

  31. PUBLIC EDUCATION • AVOID OVERCROWDING. • DO NOT SHARE DRINKING BOTTLES, GLASSES, CIGARETTES, LIPSTICKS OR OTHER ITEMS THAT MAY BE COVERED IN SALIVA. • AVOID SMOKY AND DUSTY PLACES. • TEACH CHILDREN NOT TO SHARE CUPS, SOFT DRINK CANS OR SPORTS WATER BOTTLES.

More Related